Sam Calderwood is a Consultant in the Life Sciences division at Simon-Kucher & Partners, working in the London office.
At Simon-Kucher & Partners, Sam has worked with a range of small to large pharmaceutical and healthcare companies on pricing and market access, commercialization strategy and launch sequencing projects covering a range of therapeutic areas, including oncology, immunology, dermatology and neurology. Sam's focus has been primarily within oncology, and with particular reference to the impact of international price referencing on launch sequence prioritization and oncology funding in the UK market. He has co-authored a whitepaper on the UK Cancer Drugs Fund.
Sam holds a DPhil from the University of Oxford, during which he investigated radiofluorination for Positron Emission Tomography, through classical chemistry and microfluidic platforms, publishing seven academic papers. Prior to his doctorate, his undergraduate degree was a Master of Chemistry, from the University of Oxford.